Citation: | Qiu Tao, Zhou Jiangqiao, Liu Xiuheng, et al. Comparative study of application of standard double-and single-dose of basiliximab in renal transplantation[J]. ORGAN TRANSPLANTATION, 2015, 6(4): 230-234. doi: 10.3969/j.issn.1674-7445.2015.04.005 |
[1] |
Ippoliti G, Pellegrini C, Nieswandt V. Controversies about induction therapy[J]. Transplant Proc, 2011, 43(6):2450-2452. doi: 10.1016/j.transproceed.2011.06.021
|
[2] |
Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients:how convincing is the current evidence?[J]. Drugs, 2012, 72(5):671-683. doi: 10.2165/11631300-000000000-00000
|
[3] |
Onrust SV, Wiseman LR. Basiliximab[J]. Drugs, 1999, 57(2):207-214. doi: 10.2165/00003495-199957020-00006
|
[4] |
Koch M, Becker T, Lueck R, et al. Basiliximab induction therapy in kidney transplantation:benefits for long term allograft function after 10 years?[J]. Biologics, 2009, 3:51-56. https://www.ncbi.nlm.nih.gov/pubmed/19707395
|
[5] |
Baquero A, Pérez J, Rizik N, et al. Basiliximab:a comparative study between the use of the recommended two doses versus a single dose in living donor kidney transplantation[J]. Transplant Proc, 2006, 38(3):909-910. doi: 10.1016/j.transproceed.2006.02.052
|
[6] |
Matl I, Bachleda P, Lao M, et al. Safety and efficacy of an alternative basiliximab (simulect) regimen after renal transplantation:administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine[J]. Transpl Int, 2003, 16(1):45-52. doi: 10.1111/tri.2003.16.issue-1
|
[7] |
Matl I, Bachleda P, Michalsky R, et al. Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine[J]. Transplant Proc, 2001, 33(7/8):3205-3206. http://www.ncbi.nlm.nih.gov/pubmed/11750375
|
[8] |
Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation:application of statistical approaches to reduce bias in observational comparisons[J]. Transplantation, 2009, 87(10):1520-1529. doi: 10.1097/TP.0b013e3181a484d7
|
[9] |
Wang W, Yin H, Li XB, et al. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin[J]. Chin Med J, 2012, 125(6):1135-1140. https://www.researchgate.net/publication/225052761_A_retrospective_comparison_of_the_efficacy_and_safety_in_kidney_transplant_recipients_with_basiliximab_and_anti-thymocyte_globulin
|
[10] |
Togashi J, Sugawara Y, Akamatsu N, et al. A single-center experience of the use of interleukin-2 receptor antagonists for various situations in liver transplant recipients[J]. Transplant Proc, 2014, 46(3):739-743. doi: 10.1016/j.transproceed.2013.11.075
|
[11] |
Zhao T, Yang C, Xue Y, et al. Impact of basiliximab on the proportion of regulatory T cells and their subsets early after renal transplantation:a preliminary report[J]. Transplant Proc, 2012, 44(1):175-178. doi: 10.1016/j.transproceed.2011.11.026
|
[12] |
肖序仁, 敖建华, 闵志廉, 等.肾移植受者应用舒莱的临床研究[J].中华泌尿外科杂志, 2005, 26(11):733-735. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHMN200511003.htm
Xiao XR, Ao JH, Min ZL, et al. Clinical study of simulect in renal allograft recipients[J]. Chin J Urol, 2005, 26(11):733-735. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHMN200511003.htm
|
[13] |
李健, 许亚宏, 郭瑜, 等.两种生物免疫诱导方案对肾移植受者的影响[J].器官移植, 2014, 5(5):299-303. http://www.organtranspl.com/browse/detail/qkid/32/id/193
Li J, Xu YH, Guo Y, et al. Effect of two biological immunologic induction therapies on renal transplant recipients[J]. Organ Transplant, 2014, 5(5):299-303. http://www.organtranspl.com/browse/detail/qkid/32/id/193
|
[14] |
冯小芳, 闵敏, 左富姐, 等.小剂量兔抗人胸腺细胞免疫球蛋白与抗人T细胞猪免疫球蛋白在肾移植诱导治疗中的比较[J].肾脏病与透析肾移植杂志, 2012, 21(6):530-535. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201206007.htm
Feng XF, Min M, Zuo FJ, et al. Comparison of low dose thymoglobulin and ALG-P in the induction therapy for kidney transplant recipients[J]. Chin J Nephrol Dial Transplant, 2012, 21(6):530-535. http://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201206007.htm
|
[15] |
Lo YC, Ho HC, Wu MJ, et al. Interleukin-2 receptor antagonist does not decrease biopsy-proven acute rejection among adult Chinese kidney transplant recipients[J]. Ren Fail, 2012, 34(7):856-861. doi: 10.3109/0886022X.2012.684032
|